EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

Chadi Hage Chehade iD, Georges Gebrael, Nicolas Sayegh iD, Zeynep Irem Ozay, Arshit Narang, Tony Crispino, Talia Golan, Jennifer K Litton iD, Umang Swami, Kathleen N Moore, Neeraj Agarwal

CA: A Cancer Journal for Clinicians · 2025-04 · 75 (2) · 141-167

DOI: 10.3322/caac.21870 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 10.01.2025. Verfasst von Chadi Hage Chehade und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsNeoplasmsAntineoplastic AgentsHumansFemalePhthalazinesMaleOvarian NeoplasmsPiperazinesBreast NeoplasmsClinical Trials, Phase III as TopicPiperidinesProstatic NeoplasmsIndolesIndazolesPancreatic Neoplasms

Stichwörter der Autor:innen

breast cancerovarian cancerpancreatic cancerpoly(adenosine diphosphate ribose) polymerase inhibitorsprostate cancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsrucaparibPhthalazinesAntineoplastic AgentsolaparibPiperazinesPiperidinesniraparibIndolesIndazoles

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • UsTOO Prostate Cancer Support and Education Las Vegas Chapter, Las Vegas, Nevada, USA.
  • Division of Medical Oncology, Sheba Medical Center, Tel Aviv Medical University, Tel Aviv, Israel.
  • Division of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma, USA.

ORCID-Profile: Chadi Hage Chehade, Nicolas Sayegh, Jennifer K Litton

Zitieren

APA

Hage Chehade, C., Gebrael, G., Sayegh, N., Ozay, Z. I., Narang, A., Crispino, T., Golan, T., Litton, J. K., Swami, U., Moore, K. N., & Agarwal, N. (2025). A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA: A Cancer Journal for Clinicians, 75(2), 141-167. https://doi.org/10.3322/caac.21870

Vancouver

Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, et al. A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA: A Cancer Journal for Clinicians. 2025;75(2):141-167. doi:10.3322/caac.21870

BibTeX
@article{HageChehade2025,
  author = {Hage Chehade, Chadi and Gebrael, Georges and Sayegh, Nicolas and Ozay, Zeynep Irem and Narang, Arshit and Crispino, Tony and Golan, Talia and Litton, Jennifer K and Swami, Umang and Moore, Kathleen N and Agarwal, Neeraj},
  title = {A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2025},
  volume = {75},
  number = {2},
  pages = {141--167},
  doi = {10.3322/caac.21870}
}
Kostenlos starten →